— Newly developed, state-of-the-art analytical methods confirm the integrity and quality of Oxford BioMedica’s LentiVector® platform products — Oxford, UK – 17 October 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
— UK consortium wins £7.7 million total funding, of which £7.1 million awarded to Oxford BioMedica as lead member —… Read More
Click here to download the full 2013 interim results statement.Click here to download the 2013 interim results presentation. Read More
— Phase I clinical trial for 5T4-targeted antibody therapy underway — Oxford, UK – 28 August 2013: Oxford BioMedica (“Oxford BioMedica” or “the… Read More
— Funding to be received for the development of a novel therapeutic treatment to engineer corneas to resist graft rejection — Oxford,… Read More
— Results from Phase II trial in prostate cancer published in Cancer Immunology, Immunotherapy — — Favourable tolerability and biomarker… Read More
Results date: 29 August 2013 Oxford, UK – 23 July 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, will be announcing its interim results for the six months ended 30 June… Read More
— Pre-clinical collaboration with Mayo Clinic on track — Oxford, UK – 1 July 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB),… Read More
Oxford, UK – 6 June 2013: Oxford BioMedica (“the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it has appointed Nomura Code Securities Limited as its sponsor, financial adviser and broker with immediate effect. Read More
Oxford, UK – 6 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that Dr Stuart Naylor will step down from the Board of Oxford BioMedica and as Chief Scientific Officer… Read More
Oxford, UK – 3 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it has voluntarily paused recruitment into the RetinoStat® Phase I, StarGen™ Phase I/IIa… Read More
Oxford, UK – 16 May 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 January to 15 May 2013. Read More